Ryan K Shields

List of Publications by Year
in descending order

154 papers	6,752 citations	52348 43 h-index	59442 77 g-index
160 all docs	160 docs citations	160 times ranked	6023 citing authors

#	Article	IF	Citations
1	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. Clinical Infectious Diseases, 2016, 63, 1615-1618.	5.7	373
2	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	373
3	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla _{KPC-3} Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	343
4	Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance. Clinical Infectious Diseases, 2015, 60, 1295-1303.	5.7	326
5	Performance of Candida Real-time Polymerase Chain Reaction, Â-D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis. Clinical Infectious Diseases, 2012, 54, 1240-1248.	5.7	248
6	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clinical Infectious Diseases, 2017, 65, 110-120.	5.7	234
7	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	220
8	Mutations in bla _{KPC-3} That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	160
9	The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata. Antimicrobial Agents and Chemotherapy, 2012, 56, 4862-4869.	3.4	155
10	Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplant Recipients. Clinical Infectious Diseases, 2011, 52, 1218-1226.	5.7	126
11	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	126
12	Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity. Antimicrobial Agents and Chemotherapy, 2012, 56, 2371-2377.	3.4	118
13	Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum Î²-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 5793-5797.	3.4	110
14	Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS ONE, 2016, 11, e0153247.	2.4	110
15	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature. Open Forum Infectious Diseases, 2017, 4, ofx101.	0.9	109
16	Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4443-4451.	3.4	102
17	Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from Î²-Lactamase Protein Engineering. MBio, 2017, 8, .	4.3	99
18	Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure. Antimicrobial Agents and Chemotherapy, 2013, 57, 3528-3535.	3.4	95

#	Article	IF	Citations
19	Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 7601-7605.	3.4	91
20	Mutations of the ompK36 Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella pneumoniae Strains to Doripenem and Doripenem-Colistin. Antimicrobial Agents and Chemotherapy, 2013, 57, 5258-5265.	3.4	88
21	In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	88
22	Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 3227-3231.	3.4	86
23	Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	75
24	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 2020, 71, 667-671.	5.7	74
25	Evolution of Outbreak-Causing Carbapenem-Resistant Klebsiella pneumoniae ST258 at a Tertiary Care Hospital over 8 Years. MBio, 2019, 10, .	4.3	72
26	The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2012, 56, 3395-3398.	3.4	69
27	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagnostic Microbiology and Infectious Disease, 2011, 70, 246-252.	1.9	68
28	Clinical perspectives on echinocandin resistance among Candida species. Current Opinion in Infectious Diseases, 2015, 28, 514-522.	3.1	66
29	Posaconazole Serum Concentrations among Cardiothoracic Transplant Recipients: Factors Impacting Trough Levels and Correlation with Clinical Response to Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 1308-1311.	3.4	62
30	Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	62
31	Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum. Antimicrobial Agents and Chemotherapy, 2011, 55, 2641-2647.	3.4	61
32	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime. Clinical Infectious Diseases, 2020, 71, 2713-2716.	5.7	61
33	Staphylococcus aureus infections in the early period after lung transplantation: Epidemiology, risk factors, and outcomes. Journal of Heart and Lung Transplantation, 2012, 31, 1199-1206.	0.6	59
34	Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 1897-1906.	3.4	59
35	Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum Î²-Lactams for Major Gram-Negative Bacterial Pathogens. Clinical Infectious Diseases, 2017, 65, 738-745.	5.7	59
36	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	57

#	Article	IF	Citations
37	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2018, 56, .	4.4	55
38	Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance. Antimicrobial Agents and Chemotherapy, 2013, 57, 6361-6365.	3.4	54
39	Rapid Detection of FKS -Associated Echinocandin Resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 2016, 60, 6573-6577.	3.4	53
40	Characterization of Porin Expression in Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 2147-2153.	3.4	50
41	Rate ofFKSMutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 7465-7470.	3.4	50
42	Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS ONE, 2017, 12, e0173286.	2.4	50
43	Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamaseâ€“Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. Clinical Infectious Diseases, 2022, 75, 1081-1084.	5.7	49
44	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2045-2052.	5.7	48
45	Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000â€“2017. Clinical Infectious Diseases, 2021, 73, e4521-e4530.	5.7	48
46	Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2013, 68, 922-926.	3.2	44
47	Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. Open Forum Infectious Diseases, 2017, 4, ofx102.	0.9	44
48	Aztreonam Combination Therapy: An Answer to Metallo-Î²-Lactamaseâ€“Producing Gram-Negative Bacteria?. Clinical Infectious Diseases, 2020, 71, 1099-1101.	5.7	42
49	Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections. Clinical Infectious Diseases, 2020, 71, e650-e656.	5.7	42
50	In Vitro Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem. Antimicrobial Agents and Chemotherapy, 2014, 58, 1195-1199.	3.4	41
51	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2016, 60, 3187-3192.	3.4	41
52	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. Clinical Infectious Diseases, 2021, 73, 416-426.	5.7	41
53	Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microbial Drug Resistance, 2022, 28, 398-407.	2.0	41
54	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-Î²-Lactamase-Producing Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 5208-5214.	3.4	39

#	Article	IF	Citations
55	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	39
56	Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79â€‰148 prostate-cancer cases and 61â€‰106 controls. International Journal of Epidemiology, 2020, 49, 587-596.	2.1	39
57	Polymyxin-Resistant Acinetobacter baumannii: Urgent Action Needed. Clinical Infectious Diseases, 2015, 60, 1304-7.	5.7	38
58	In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.4	37
59	Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. International Journal of Antimicrobial Agents, 2014, 44, 557-563.	3.4	36
60	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing Klebsiella pneumoniae Strains with Various ompK36 Genotypes. Antimicrobial Agents and Chemotherapy, 2014, 58, 3521-3525.	3.4	35
61	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infectious Diseases, 2016, 16, 655.	3.0	34
62	In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA. Microbiology Spectrum, 2021, 9, e0177921.	3.0	34
63	Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	33
64	Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant Klebsiella pneumoniae Bacteriuria. Antimicrobial Agents and Chemotherapy, 2014, 58, 3100-3104.	3.4	32
65	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	31
66	The structure of human EXD2 reveals a chimeric 3â€² to 5â€² exonuclease domain that discriminates substrates via metal coordination. Nucleic Acids Research, 2019, 47, 7078-7093.	14.2	30
67	Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections. Clinical Infectious Diseases, 2021, 73, e1754-e1757.	5.7	30
68	Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists. Infectious Diseases and Therapy, 2021, 10, 2177-2202.	4.2	30
69	Structural Characterization of the D179N and D179Y Variants of KPC-2 Î²-Lactamase: Î©-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2022, 66, e0241421.	3.4	27
70	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	26
71	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. Diagnostic Microbiology and Infectious Disease, 2019, 95, 114856.	1.9	26
72	Doripenem MICs and ompK36 Porin Genotypes of Sequence Type 258, KPC-Producing Klebsiella pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 1797-1801.	3.4	25

#	Article	IF	Citations
73	Spontaneous fungal peritonitis: a devastating complication of cirrhosis. Mycoses, 2015, 58, 387-393.	4.2	24
74	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades. Journal of Clinical Microbiology, 2020, 58, .	4.4	24
75	Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2022, 74, 395-406.	5.7	23
76	Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia. Clinical Infectious Diseases, 2022, 75, 710-714.	5.7	23
77	Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin. Antimicrobial Agents and Chemotherapy, 2016, 60, 3090-3095.	3.4	21
78	Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	20
79	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	20
80	KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6â€²)-Ib Exhibit Intermediate Resistance to Amikacin. Antimicrobial Agents and Chemotherapy, 2014, 58, 7597-7600.	3.4	19
81	Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo GalleriaÂmellonella survival model analysis. International Journal of Antimicrobial Agents, 2020, 55, 105852.	3.4	19
82	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii. Antibiotics, 2021, 10, 880.	3.8	19
83	Genomic Analysis Reveals Potential Mechanisms Underlying Promotion of Tomato Plant Growth and Antagonism of Soilborne Pathogens by Bacillus amyloliquefaciens Ba13. Microbiology Spectrum, 2021, 9, e0161521.	3.0	18
84	Five-Minute Exposure to Caspofungin Results in Prolonged Postantifungal Effects and Eliminates the Paradoxical Growth of Candida albicans. Antimicrobial Agents and Chemotherapy, 2011, 55, 3598-3602.	3.4	16
85	Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	15
86	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3558-3562.	3.4	14
87	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	14
88	Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrugâ€resistant Burkholderia multivorans. Transplant Infectious Disease, 2023, 25, .	1.7	14
89	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 3585-3587.	3.2	13
90	1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa. Open Forum Infectious Diseases, 2018, 5, S419-S420.	0.9	13

#	Article	IF	Citations
91	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Journal of Antimicrobial Chemotherapy, 2020, 75, 3023-3028.	3.2	13
92	High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.4	12
93	Back to Square One: Revisiting How We Analyse the Right of Access to Environmental Information. Journal of Environmental Law, 2019, 31, 465-485.	1.3	12
94	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, e0212421.	3.4	12
95	Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa549.	0.9	11
96	Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Infection and Immunity, 2022, 90, e0000122.	2.4	11
97	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. Journal of Fungi (Basel, Switzerland), 2016, 2, 10.	3.6	10
98	Longitudinal Clinical Trial Recruitment and Retention Challenges in the Burn Population: Lessons Learned From a Trial Examining a Novel Intervention for Chronic Neuropathic Symptoms. Journal of Burn Care and Research, 2019, 40, 792-795.	0.5	10
99	Application of Combined Genomic and Transfer Analyses to Identify Factors Mediating Regional Spread of Antibiotic-resistant Bacterial Lineages. Clinical Infectious Diseases, 2020, 71, e642-e649.	5.7	10
100	Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome. Scandinavian Journal of Infectious Diseases, 2012, 44, 982-986.	1.5	9
101	Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci. Microbiology Spectrum, 2023, 11, .	3.0	9
102	Within-Host Genotypic and Phenotypic Diversity of Contemporaneous Carbapenem-Resistant Klebsiella pneumoniae from Blood Cultures of Patients with Bacteremia. MBio, 2022, 13, .	4.3	8
103	Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients. Journal of Antimicrobial Chemotherapy, 2023, 78, 1034-1040.	3.2	7
104	Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS -Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	6
105	High-level ceftazidime/avibactam resistance inEscherichia coliconferred by the novel plasmid-mediated Î²-lactamase CMY-185 variant. Journal of Antimicrobial Chemotherapy, 2023, 78, 2442-2450.	3.2	6
106	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258. Journal of Antimicrobial Chemotherapy, 2019, 74, 2203-2208.	3.2	5
107	Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis. Open Forum Infectious Diseases, 2023, 10, .	0.9	5
108	In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel Î²-lactam/Î²-lactamase inhibitors. JAC-Antimicrobial Resistance, 2023, 5, .	2.2	5

#	Article	IF	Citations
109	Reply to Tang and Lai. Clinical Infectious Diseases, 2020, 71, 1583-1583.	5.7	4
110	Impact ofompk36genotype and KPC subtype on thein vitroactivity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producingK. pneumoniaeclinical isolates. JAC-Antimicrobial Resistance, 2023, 5, .	2.2	4
111	Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis. Journal of Infection and Chemotherapy, 2022, 28, 87-90.	1.7	3
112	Candida Biofilm: Clinical Implications of Recent Advances in Research. Current Fungal Infection Reports, 2014, 8, 72-80.	2.5	2
113	Enantioselective UFLC Determination of Hydroxyzine Enantiomers and Application to a Pharmacokinetic Study in Rabbits. Journal of Chromatographic Science, 2016, 54, 1806-1812.	1.5	2
114	Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. Journal of Chemotherapy, 2022, 34, 345-346.	1.5	2
115	Impact of Rapid Identification and Stewardship Intervention on Coagulase-Negative Staphylococcus Bloodstream Infection. Open Forum Infectious Diseases, 2023, 10, .	0.9	2
116	Serratia endocarditis: antimicrobial management strategies and clinical outcomes. Journal of Antimicrobial Chemotherapy, 2023, 78, 2457-2461.	3.2	2
117	Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia. Clinical Infectious Diseases, 0, , .	5.7	2
118	Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy (OPAT) Program Failure Among Intravenous Drug Users (IVDUs). Open Forum Infectious Diseases, 2016, 3, .	0.9	1
119	Rapid Emergence of Ceftazidime-Avibactam Resistance Due to blaKPC-3 Mutations During Treatment (tx) of Carbapenem-Resistant Klebsiella pneumoniae (CRKp) Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
120	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. Open Forum Infectious Diseases, 2018, 5, S729-S729.	0.9	1
121	2420. A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections. Open Forum Infectious Diseases, 2018, 5, S723-S724.	0.9	1
122	2033. Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients At-Risk for Sepsis due to Invasive Candidiasis (IC). Open Forum Infectious Diseases, 2018, 5, S592-S593.	0.9	1
123	Sequence type-258 carbapenem-resistant Klebsiella pneumoniae isolates in which ceftazidimeâ€“avibactam resistance emerged are not hypermutators. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114954.	1.9	1
124	Interventional Study of Dextromethorphan Abuse Within the U.S. Military Community in Okinawa, Japan. Military Medicine, 2020, 185, e926-e929.	0.9	1
125	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. Open Forum Infectious Diseases, 2021, 8, ofaa571.	0.9	1
126	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates. Phage, 2022, 3, 50-58.	2.1	1

#	Article	IF	Citations
127	Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. JAC-Antimicrobial Resistance, 2023, 5, .	2.2	1
128	Stewardship-Guided T2Candida Testing Shortens Time to Antifungal Treatment and Reduces Antifungal Usage Among Medical Intensive Care Unit Patients With Septic Shock. Open Forum Infectious Diseases, 2023, 10, .	0.9	1
129	Structural insights into the molecular mechanism of high-level ceftazidimeâ€“avibactam resistance conferred by CMY-185. MBio, 2024, 15, .	4.3	1
130	Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. MBio, 2024, 15, .	4.3	1
131	Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres. Journal of Global Antimicrobial Resistance, 2024, 37, 190-194.	2.5	1
132	Outcomes of Candida Empyema Correlate with Source of Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
133	Outcomes Comparing Initial Fluconazole to Micafungin in ICU Patients with Candidemia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
134	Retrospective Study of Outcomes Comparing Initial Treatment with Fluconazole or Micafungin in Immunosuppressed Patients with Candidemia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
135	Daptomycin Non-susceptible VRE: Problematic Pathogen or Misclassified Microbe?. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
136	Impact of Rectal Colonization With Highly Drug-Resistant Enterobacteriaceae on Post-Transplant Infections: The Carbapenem-Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
137	Emerging Waves of Carbapenem Resistance Among Gram-Negative Pathogens at a Tertiary Center. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
138	Clinical Outcomes of Bloodstream Infections Due to Vancomycin-Resistant Enterococcus faecium. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
139	Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. Open Forum Infectious Diseases, 2017, 4, S297-S297.	0.9	0
140	2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses. Open Forum Infectious Diseases, 2018, 5, S724-S724.	0.9	0
141	1064. Clinical Outcomes of Daptomycin in Combination With Ceftaroline or Anti-Staphylococcal Penicillins for Patients With Persistent MRSA Bacteremia. Open Forum Infectious Diseases, 2018, 5, S318-S318.	0.9	0
142	1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents. Open Forum Infectious Diseases, 2018, 5, S474-S474.	0.9	0
143	2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia. Open Forum Infectious Diseases, 2018, 5, S717-S718.	0.9	0
144	247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria. Open Forum Infectious Diseases, 2018, 5, S105-S105.	0.9	0

#	Article	IF	Citations
145	357. Aspergillus Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program Using Azole Prophylaxis. Open Forum Infectious Diseases, 2018, 5, S140-S140.	0.9	0
146	706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp). Open Forum Infectious Diseases, 2018, 5, S254-S254.	0.9	0
147	STUDI AWAL ADAPTASI ALAT UKUR LEISURE SATISFACTION DI INDONESIA. Personifikasi, 2021, 12, 105-125.	0.1	0
148	Antimicrobial Agents and Chemotherapy Launches a New Section Focused on Innovative Antimicrobial Stewardship Studies. Antimicrobial Agents and Chemotherapy, 2023, 67, .	3.4	0
149	Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates. Journal of Antimicrobial Chemotherapy, 2024, 79, 801-809.	3.2	0
150	Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in Escherichia coliâ€“Caused Uncomplicated Urinary Tract Infection. Clinical Infectious Diseases, 0, , .	5.7	0
151	Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
152	Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
153	Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
154	Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis. Infectious Diseases and Therapy, 2024, 13, 1639-1664.	4.2	0